225. Keefe JR, Mao JJ, Soeller I, Li QS, Amsterdam JD. Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder. Phytomedicine. 2016;23:1699–1705. https:// pubmed.ncbi.nlm.nih.gov/27912871/
226. Mao JJ, Xie SX, Keefe JR, Soeller I, Li QS, Amsterdam JD. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: a randomized clinical trial. Phytomedicine. 2016;23:1735–42. https://pubmed.ncbi.nlm.nih.gov/27912875/
227. Shakeri A, Sahebkar A, Javadi B. Melissa officinalis L. – a review of its traditional uses, phytochemistry and pharmacology. J Ethnopharmacol. 2016;188:204–28. https://pubmed.ncbi.nlm.nih.gov/27167460/
228. Kennedy DO, Scholey AB, Tildesley NTJ, Perry EK, Wesnes KA. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav. 2002;72:953–64. https:// pubmed.ncbi.nlm.nih.gov/12062586/
229. Kennedy DO, Wake G, Savelev S, Tildesley NTJ, Perry EK, Wesnes KA, et al. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology. 2003;28:1871–81. https://pubmed.ncbi.nlm.nih.gov/12888775/
230. Kennedy DO, Little W, Scholey AB. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (lemon balm). Psychosom Med. 2004;66:607–13. https://pubmed.ncbi.nlm.nih.gov/ 15272110/
231. Scholey A, Gibbs A, Neale C, Perry N, Ossoukhova A, Bilog V, et al. Antistress effects of lemon balm-containing foods. Nutrients. 2014;6:4805–21. https://pubmed.ncbi.nlm.nih.gov/25360512/
232. Cases J, Ibarra A, Feuillère N, Roller M, Sukkar SG. Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mildto-moderate anxiety disorders and sleep disturbances. Med J Nutrition Metab. 2011;4:211–18. https://pubmed.ncbi.nlm.nih.gov/22207903/
233. Müller SF, Klement S. A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine. 2006;13:383–87. https://pubmed.ncbi.nlm.nih.gov/16487692/
234. Taavoni S, Nazem Ekbatani N, Haghani H. Valerian/lemon balm use for sleep disorders during menopause. Complement Ther Clin Pract. 2013;19:193–96. https://pubmed.ncbi.nlm.nih.gov/24199972/
235. Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017;34:10–22. https://pubmed.ncbi.nlm.nih.gov/28648359/
236. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8:e63773. https:// pubmed.ncbi.nlm.nih.gov/23691095/
237. Li T, Jiang S, Han M, Yang Z, Lv J, Deng C, et al. Exogenous melatonin as a treatment for secondary sleep disorders: a systematic review and metaanalysis. Front Neuroendocrinol. 2019;52:22–8. https://pubmed.ncbi.nlm.nih.gov/29908879/
238. Wang Y-Y, Zheng W, Ng CH, Ungvari GS, Wei W, Xiang Y-T. Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer’s disease. Int J Geriatr Psychiatry. 2017;32:50–57. https://pubmed.ncbi.nlm.nih.gov/27645169/
239. Zhang W, Chen X-Y, Su S-W, Jia Q-Z, Ding T, Zhu Z-N, et al. Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol Sci. 2016;37:57–65. https://pubmed.ncbi.nlm.nih.gov/26255301/
240. Abdelgadir IS, Gordon MA, Akobeng AK. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. Arch Dis Child. 2018;103:1155–62. https:// pubmed.ncbi.nlm.nih.gov/29720494/
241. Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol. 2011;53:783–92. https:// pubmed.ncbi.nlm.nih.gov/21518346/
242. Doosti-Irani A, Ostadmohammadi V, Mirhosseini N, Mansournia MA, Reiter RJ, Kashanian M, et al. The effects of melatonin supplementation on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Horm Metab Res. 2018;50:783–90. https://pubmed.ncbi.nlm.nih.gov/30396207/
243. Akbari M, Ostadmohammadi V, Mirhosseini N, Lankarani KB, Tabrizi R, Keshtkaran Z, et al. The effects of melatonin supplementation on blood pressure in patients with metabolic disorders: a systematic review and metaanalysis of randomized controlled trials. J Hum Hypertens. 2019;33:202–9. https://pubmed.ncbi.nlm.nih.gov/30647466/
244. Akbari M, Ostadmohammadi V, Tabrizi R, Lankarani KB, Heydari ST, Amirani E, et al. The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials. Inflammopharmacology. 2018;26:899–907. https://pubmed.ncbi.nlm.nih.gov/29907916/
245. Morvaridzadeh M, Sadeghi E, Agah S, Nachvak SM, Fazelian S, Moradi F, et al. Effect of melatonin supplementation on oxidative stress parameters: a systematic review and meta-analysis. Pharmacol Res. 2020;161:105210. https://pubmed.ncbi.nlm.nih.gov/33007423/
246. Ghorbaninejad P, Sheikhhossein F, Djafari F, Tijani AJ, Mohammadpour S, Shab-Bidar S. Effects of melatonin supplementation on oxidative stress: a systematic review and meta-analysis of randomized controlled trials. Horm Mol Biol Clin Investig. 2020;41. http://dx.doi.org/10.1515/hmbci-2020-0030
247. van Heukelom RO, Prins JB, Smits MG, Bleijenberg G. Influence of melatonin on fatigue severity in patients with chronic fatigue syndrome and late melatonin secretion. Eur J Neurol. 2006;13:55–60. https://pubmed.ncbi.nlm.nih.gov/16420393/
248. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother. 2006;60:97–108. https://pubmed.ncbi.nlm.nih.gov/16527442/
249. Morgan PJ, Barrett P, Howell HE, Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int. 1994;24:101–46. https://pubmed.ncbi.nlm.nih.gov/ 8161940/
250. Harpsøe NG, Andersen LPH, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71:901–9. https://pubmed.ncbi.nlm.nih.gov/26008214/
251. Matsumoto M, Sack RL, Blood ML, Lewy AJ. The amplitude of endogenous melatonin production is not affected by melatonin treatment in humans. J Pineal Res. 1997;22:42–44. https://pubmed.ncbi.nlm.nih.gov/9062869/
252. Wright J, Aldhous M, Franey C, English J, Arendt J. The effects of exogenous melatonin on endocrine function in man. Clin Endocrinol. 1986;24:375–82. https://pubmed.ncbi.nlm.nih.gov/3742833/
253. Arendt J, Bojkowski C, Folkard S, Franey C, Marks V, Minors D, et al. Some effects of melatonin and the control of its secretion in humans. Ciba Found Symp. 1985;117:266–83. https://pubmed.ncbi.nlm.nih.gov/3836818/
254. Matsumoto, Sack, Blood, Lewy. The amplitude of endogenous melatonin production is not affected by melatonin treatment in humans. J Pineal Res. 1997;22(1):42–44. https://onlinelibrary.wiley.com/doi/10.1111/j.1600-079X.1997.tb00301.x
255. Dhawan K, Kumar R, Kumar S, Sharma A. Correct identification of Passiflora incarnata Linn., a promising herbal anxiolytic and sedative. J Med Food. 2001;4:137–44. https://pubmed.ncbi.nlm.nih.gov/12639407/
256. da Fonseca LR, Rodrigues R de A, Ramos A de S, da Cruz JD, Ferreira JLP, Silva JR de A, et al. Herbal medicinal products from Passiflora for anxiety: an unexploited potential. ScientificWorldJournal. 2020;2020:6598434. https:// www.hindawi.com/journals/tswj/2020/6598434/
257. Lee J, Jung H-Y, Lee SI, Choi JH, Kim S-G. Effects of Passiflora incarnata Linnaeus on polysomnographic sleep parameters in subjects with insomnia disorder: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol. 2020;35:29–35. https://pubmed.ncbi.nlm.nih.gov/ 31714321/
258. Ngan A, Conduit R. A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality. Phytother Res. 2011;25:1153–59. https://pubmed.ncbi.nlm.nih.gov/ 21294203/
259. Guerrero FA, Medina GM. Effect of a medicinal plant (Passiflora incarnata L) on sleep. Sleep Sci. 2017;10:96–100. https://pubmed.ncbi.nlm.nih.gov/ 29410738/
260. Kim G-H, Yi SS. Chronic oral administration of Passiflora incarnata extract has no abnormal effects on metabolic and behavioral parameters in mice, except to induce sleep. Lab Anim Res. 2019;35:31. https://labanimres.biomedcentral.com/articles/10.1186/s42826-019-0034-9
261. Movafegh A, Alizadeh R, Hajimohamadi F, Esfehani F, Nejatfar M. Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesth Analg. 2008;106:1728–32. https://pubmed.ncbi.nlm.nih.gov/18499602/
262. Aslanargun P, Cuvas O, Dikmen B, Aslan E, Yuksel MU. Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. J Anesth. 2012;26:39–44. https://pubmed.ncbi.nlm.nih.gov/22048283/
263. Dantas L-P, de Oliveira-Ribeiro A, de Almeida-Souza L-M, Groppo F-C. Effects of passiflora incarnata and midazolam for control of anxiety in patients undergoing dental extraction. Med Oral Patol Oral Cir Bucal. 2017;22:e95–101. https://pubmed.ncbi.nlm.nih.gov/27918731/
264. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001;26:363–67. https://pubmed.ncbi.nlm.nih.gov/11679026/